A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > REGULATORY
REGULATORY
- Health Minister Denies November Plan for Avigan's COVID-19 OK
October 7, 2020
- MHLW Panel Approves 18th Edition of Japanese Pharmacopoeia; 33 New Products Added
October 7, 2020
- Label Revisions Ordered for Takecab, 2 Other Drugs
October 7, 2020
- MHLW Lays Out Compliance Guidelines for Manufacturers; Introduction Planned in August 2021 under Amended PMD Law
October 6, 2020
- Scrap Income Limit for Fertility Treatment Subsidies: LDP Lawmakers
October 5, 2020
- MHLW to Draft Guidelines by Year-End on Use of Patient Registry Data in Drug Filing
October 5, 2020
- PMDA to Offer Free Consultations for COVID-19 Vaccines
October 2, 2020
- MHLW Bankrolls 3 Projects Aiming to Manufacture Key APIs, Raw Materials in Japan
October 2, 2020
- MHLW’s Review Division Head Stresses Evidence-Based Approval for Coronavirus Vaccines
October 1, 2020
- Metformin Cancer Risk Acceptable at 1 in 550,000 Patients: NIHS Assessment
October 1, 2020
- MHLW Submits FY2021 Budget, Personnel Requests
October 1, 2020
- Priority Shots for Seasonal Flu Begin for Elderly, Other High-Risk People
October 1, 2020
- Rotavirus Vaccines Now Covered by National Immunization Program
October 1, 2020
- Independent Monitoring Panel Kicks Off Discussions; MHLW-PMDA Collaboration, Ad Rules among Topics
September 30, 2020
- Kentaro Enomoto to Take Over Councilor Post for Health Insurance on October 1: MHLW
September 30, 2020
- MHLW Urges Healthcare Stakeholders to Comply with Distribution Guidelines Even in COVID-19 Outbreak
September 30, 2020
- MHLW Pharma Bureau Seeks 13 Billion Yen for FY2021, Eyes Vaccine Quality Assurance Guidance in COVID-19 Quota
September 29, 2020
- MHLW Seeks Nearly 33 Trillion Yen in Unusual Budget Request for FY2021; COVID-19 Quota Yet to Come
September 29, 2020
- MHLW’s Health Policy Bureau Requests New Budgets to Forge Clinical Trial Network in Asia
September 29, 2020
- Coronavirus Panel OKs Interim Report on COVID-19 Vaccination, Sorts Out Roles of Central, Local Govts
September 29, 2020
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…